1. Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours
   ALESSANDRA CAPODANNO et al, 2012 CrossRef
2. Targeted therapies for small cell lung cancer: Where do we stand?
   Alexandre Arcaro, 2015, Critical Reviews in Oncology/Hematology CrossRef
3. Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study
   Xin-Gang Bi et al, 2017 CrossRef
4. Expression of the phosphorylated variant of the AKT1-kinase (p-AKT1) in well-differentiated pancreatic neuroendocrine tumors: immunohistochemical evaluation
   V. V. Delektorskaya et al, 2018, Alʹm. klin. med. CrossRef
5. Neuroendocrine Tumor of Lung and Mediastinum: the Updated Pathological Diagnosis and Treatment
   Yasushi Goto et al, 2019, Haigan CrossRef
6. Systemic treatment for lung carcinoids: from bench to bedside
   Mariangela Torniai et al, 2019, Clin Trans Med CrossRef
7. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study.
   Hui-Jen Tsai et al, 2013, PLoS One CrossRef
8. Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors
   Zhi Rong Qian et al, 2013, JCO CrossRef
9. PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
   Lei Wang et al, 2014, PLoS ONE CrossRef
10. Interferon alpha and rapamycin inhibit the growth of carcinoid and medullary thyroid cancer in vitro
    Ewelina Motylewska et al, 2014, Pharmacological Reports CrossRef
11. Renal epithelioid angiomyolipoma with malignant features: Histological evaluation and novel immunohistochemical findings
    Sachiko Konosu-Fukaya et al, 2014, Pathol Int CrossRef
12. Therapeutic Biomarkers in Lung Neuroendocrine Neoplasia
    Luisella Righi et al, 2014, Endocr Pathol CrossRef
13. Akt as a potential prognostic marker in neuroendocrine tumors: a possibility?
    Angela Hague et al, 2016, International Journal of Endocrine Oncology CrossRef
14. Pulmonary Large-Cell Neuroendocrine Carcinoma: Therapeutic Challenges and Opportunities
    Georgios Ioannidis, 2020 CrossRef
15. null
    Krista Noonan et al, 2018 CrossRef
16. Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance
    Sonia Bortolotti et al, 2023, Cancers CrossRef
17. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: where are we in 2023?
    Nicola Fazio et al, 2023, Best Practice & Research Clinical Endocrinology & Metabolism CrossRef
18. Expression of mTOR in normal and pathological conditions
    A Marques-Ramos et al, 2023, Mol Cancer CrossRef
19. Current understanding of pathogenetic mechanisms in neuroendocrine neoplasms
    Roberta Modica et al, 2023, Expert Review of Endocrinology & Metabolism CrossRef
20. Increased mTOR activity and RICTOR copy number in small cell lung carcinoma progression
    Dániel Sztankovics et al, 2024, European Journal of Cell Biology CrossRef